发明名称 |
COMPOSITION FOR THE TREATMENT OF PROSTATE CANCER |
摘要 |
Provided is the use of degarelix or a pharmaceutically acceptable salt thereof in the manufacture of a medicament for the treatment of prostate cancer, wherein the medicament comprises a Iyophilisate of degarelix and an excipient dissolved in a solvent, and is administered to a patient at a starting dose of between 200 and 300 mg of degarelix at a concentration of between 20 and 80 mg of degarelix per mL solvent; followed 14- 56 days after the starting dose by a maintenance dose of between 320 and 550 mg of degarelix at a concentration of between 50 and 80 mg degarelix per mL solvent; optionally followed by one or more further maintenance doses of between 320 and 550 mg of degarelix at a concentration of between 50 and 80 mg dega'relix per mL solvent administered with an interval of 56 days to 112 days between each maintenance dose.
|
申请公布号 |
NZ595767(A) |
申请公布日期 |
2012.12.21 |
申请号 |
NZ20100595767 |
申请日期 |
2010.04.30 |
申请人 |
FERRING BV |
发明人 |
OLESEN, TINE, KOLD;CANTOR, PER;ERICHSEN, LARS |
分类号 |
A61K9/00 |
主分类号 |
A61K9/00 |
代理机构 |
|
代理人 |
|
主权项 |
|
地址 |
|